Zeng J, Mao WM, Chen QX, et al. - In patients with early-stage non-small-cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutations, researchers analyzed how health-related quality of life (HRQoL) changed with adjuvant gefitinib vs chemotherapy. Via randomization (1:1), either gefitinib for 24 months or vinorelbine plus cisplatin (VP) every 3 weeks for four cycles was administered to patients with completely resected, stage II–IIIA (N1–N2), EGFR-mutant NSCLC in the phase III ADJUVANT trial. Compared with VP, time to deterioration in HRQoL was delayed with gefitinib. Findings revealed improved HRQoL in relation to treatment with adjuvant gefitinib vs VP, supporting the use of adjuvant gefitinib in patients with stage II–IIIA (N1–N2), EGFR-mutant NSCLC.